Amarin Plans Additional Phase III Trial For Miraxion To Support Huntington's NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.